key: cord-0950459-2dx8acev
authors: Bzowyckyj, Andrew
title: Critical policy passed during historic HoD
date: 2020-07-23
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2020.06.001
sha: 802437cd55a5e76081832d1bea9901a8680bf4ae
doc_id: 950459
cord_uid: 2dx8acev

nan

pharmacist, student pharmacist, and technician should challenge themselves to be an advocate. No matter how you choose to advocate, if each of us speaks out, we can create the changes we wish to see in pharmacy.

Zachary Hitchcock, fourth-year Student Pharmacist, University of MissourieKansas City at Missouri State University, Springfield, MO; 2019e20 APhAeASP Region 6 Regional Delegate

Steadying the ship through rough and uncharted waters

Rather than filling a ballroom in National Harbor, MD, delegates to the APhA House engaged from their living rooms or makeshift offices, most likely wearing comfortable pants. Below is a summary of the policies that were passed by this year's APhA House of Delegates from the perspective of a practitioner and member of APhAeAPPM.

With nearly 3.8 million prescription medications filled at a pharmacy in 2019, it is imperative that our pharmaceutical supply chain remains safe. 1 However, it remains vulnerable to multiple threats, which can undermine patient access to life-sustaining medications. For example, nearly 40% of the finished drugs and 80% of the active pharmaceutical ingredients are manufactured overseas. 2 In the setting of a global pandemic, it becomes increasingly difficult to ensure continued manufacturing and transport of these ingredients from the source countries. Furthermore, our own domestic supply chain is equally vulnerable.

Hurricane Maria was able to exacerbate an existing shortage of 0.9% sodium chloride when it destroyed parts of Puerto Rico in 2017. 3 Drug shortages can also occur as a result of countless other problems. Throughout 2019 and in the first quarter of 2020, more than 250 active national drug shortages have been consistently listed, even before coronavirus disease (COVIDe19) entered our lives. 4 In our current pharmaceutical supply chain setup, there is minimal room for error with no intentional redundancies to help safeguard our nation's supply of necessary medications. This is a substantial public health and national security issue that requires urgent attention and action.

As pharmacists' roles on health care teams continue to expand, it is extremely important to address the issue of accountability. For example, collaborative practice agreements have been instrumental in delegating authority to pharmacists. In this collaboration, it is equally important for pharmacists to not only accept the privileges, but also to accept the accountability for their clinical decision-making. Pharmacists' undertook an oath to assure optimal outcomes for patients. However, unintentional adverse effects are unavoidable, and it is important that pharmacists accept accountability for those.

A concern introduced by our delegation was that the first statement might have been inadvertently too broad. Although we agreed with the sentiment, we felt that the clarifier "within their role on the health care team" was necessary at the end of the statement to keep it focused on only the elements over which a pharmacist has direct oversight. We supported the concept that pharmacists' professional accountability should accompany increased responsibilities, but we also felt that the pharmacist's specific role in a given scenario could potentially limit how much a pharmacist can actually be held accountable for.

A steadily increasing number of medications getting approved are complex to manage and/or require more specialized care and resources, thereby warranting an appropriate use of the term "specialty medications." Patients need pharmacists who are interested in pursuing additional education and training with these novel medications. In addition, the establishment of specialty pharmacies and/or the incorporation of specialty pharmacy services into existing practices can also help meet patients' needs. However, this seemingly benign term can result in substantial barriers for patients, including higher out-of-pockets costs and restrictions on where to obtain the medication(s). Furthermore, the use of restrictive specialty pharmacy networks and/or manufacturer distribution removes the patient's choice in this matter, in addition to further fragmenting the patient's care. Ultimately, it should be the patient's right to obtain his or her medications from the source he or she chooses.

In addition to the policies proposed by the 2019e2020 APhA Policy Committee, 15 New Business Items (NBIs) were also considered. Of these, 3 NBIs were submitted by APhAeAPPM and passed in the House. These topics included: E-prescribing standardization, Community-based pharmacists as providers of care, and Integrated Nationwide Prescription Drug Monitoring program. Because of the abundance of policy items, highlighted below are a handful of policies that were discussed the most by our delegation.

Our health care system is ill-equipped to serve a large volume of people in a timely and efficient manner, without utilizing every available member of the health care team to their fullest potential, including the pharmacists. Communitybased pharmacists are conveniently located and frequently offer extended hours at times when traditional clinics are closed. Rather than instinctively referring all patients to an already crowded emergency room, a more costeffective approach may be to triage the patient at the local community pharmacy. While not every medical condition will be within the pharmacist's expertise, there are some chronic conditions and acute ailments that pharmacists can safely and effectively assess and treat. This forward-thinking policy is a conversation starter for operationalizing this patient care model. As an example, the U.S. Department of Health & Human Services recently authorized pharmacists to order and administer COVIDe19 testing. 5 However, to ensure practice sustainability and continued patient access, appropriate remuneration for the pharmacist's clinical assessment is 

The U.S. health insurance system continues to function in 2 isolated silos: the medical benefit and the pharmacy benefit, with pharmacists straddling both sides. This traditional health insurance mindset does not easily accommodate pharmacist interventions, which often show an increase in spending on medications, which is offset of a larger decrease in the overall direct health care costs. Why should a prescription drug plan foot the bill when the company underwriting the medical benefit is reaping the benefit?

If the pharmacy and medical benefits were coordinated together, health care dollars can be saved and focused on improving patient outcomes, so long as patients maintain the right to choose their providers for these benefits.

This topic certainly garnered a lot of discussion among the APhAeAPPM delegation. The profession has worked very hard to validate pharmacists' role in this public health space to the point where pharmacist-administered vaccines are now a societal norm. However, the pharmacist's expertise is best leveraged during the decision-making process for which vaccines are indicated and for the management of anaphylactic emergencies. The administration of the actual injection does not require clinical oversight.

As a corollary example, the physician evaluates a patient's candidacy for a vaccine, but it is the medical assistant who actually administers the injection. 6 If pharmacists are going to take on more responsibilities as health care providers fully integrated within the care team, we will not be able to do it all, and the skillset of the whole pharmacy team needs to be leveraged appropriately.

During the early days of the COVIDe19 crisis, pharmacy teams across the country were frequently operating without implementing significant protection and control measures. In the weeks following the approval of this policy, there appears to be significant improvements on this front. APhA should continue to solicit input from individual members to ensure that the requests outlined in this policy are appropriately honored.

At the time this article was written, Food and Drug Administration (FDA) had already issued warning letters in response to 50 different products that are either unapproved or asserting false or misleading claims, and this number is increasing daily. 7 Likewise, as diagnostic tests, treatments, and an eventual vaccine become available, the demand for these products will be immense, and it is essential to protect patients from price gouging.

Although it is certainly much more fun to listen to other's perspectives, live during the open hearings and sit in the large ballroom to see the policy-making process in action, we are truly fortunate to be able to still accomplish the work of the House while remaining safe in our homes during the ongoing pandemic.

Number of retail prescription drugs filed at pharmacies by payer

United States Government Accountability Office. Preliminary findings indicate persistent challenges with FDA foreign inspections

Saline shortages e many causes, no simple solution

American Society of Health-System Pharmacists. Drug shortage statistics

APhA coronavirus watch: licensed pharmacists can test for COVID-19, HHS says

American Association of Medical Assistants

Food & Drug Administration. Fraudulent coronavirus disease 2019 (COVID-19) products

Dedicated delegates rise to the challenge It has been a wild ride for all of us these last few months, but APhA has been able to continue its work amid the chaos of coronavirus disease (COVID-19). When faced with the unprecedented challenge of travel restrictions that prevented a live Annual Meeting, the APhA staff and Academy officers quickly rallied to create a virtual experience. For the first time in the history of the Association, we conducted a virtual House of Delegates (HOD).In preparing for the HOD, we asked the APhAeAPRS delegates to participate in 2 virtual caucuses. I was excited to find that nearly all of our delegates were able to join both caucuses and the HOD live session. I truly appreciate the dedication of our delegates! Given the challenge of conducting the business of the HOD in a virtual session, we had to modify the rules and schedule of the HOD. One of the biggest changes was to allow online voting by delegates before the HOD session. The delegates voted through a secure Web portal on the 3 policies recommended by the APhA Policy Committee, as well as 12 New Business Items (NBIs) submitted by members. These 15 policies under consideration included 53 unique statements on which the delegates voted. All but 4 of the statements received a majority vote in favor of the statement and were adopted as APhA policy.

During the live virtual session of the HOD on March 20 afternoon, the delegates considered 3 urgent NBIs submitted by the APhA Board of Trustees. These NBIs all pertained to the COVID-19 Nau